77 related articles for article (PubMed ID: 9404480)
1. RAS and the myelodysplastic syndromes.
Gallagher A; Darley R; Padua RA
Pathol Biol (Paris); 1997 Sep; 45(7):561-8. PubMed ID: 9404480
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
[TBL] [Abstract][Full Text] [Related]
3. N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation.
Shen S; Passioura T; Symonds G; Dolnikov A
Exp Hematol; 2007 Jun; 35(6):908-19. PubMed ID: 17533045
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of p21RAS but not p120GAP is a common feature of myelodysplasia.
Gallagher A; Padua RA; al-Sabah A; Hoy T; Burnett AK; Darley RL
Leukemia; 1995 Nov; 9(11):1833-40. PubMed ID: 7475271
[TBL] [Abstract][Full Text] [Related]
5. ras mutations in human leukemia and related disorders.
Greenberger JS
Int J Cell Cloning; 1989 Nov; 7(6):343-59. PubMed ID: 2681441
[TBL] [Abstract][Full Text] [Related]
6. Analysis of immunohistochemical results of the ras oncogene product p21 in myelodysplastic syndromes.
Kalmantis T; Kalmanti M; Vassilaki M; Spandidos DA
Anticancer Res; 1993; 13(4):1103-6. PubMed ID: 8352532
[TBL] [Abstract][Full Text] [Related]
7. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.
Hirai H; Kobayashi Y; Mano H; Hagiwara K; Maru Y; Omine M; Mizoguchi H; Nishida J; Takaku F
Nature; 1987 Jun 4-10; 327(6121):430-2. PubMed ID: 3295562
[TBL] [Abstract][Full Text] [Related]
8. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA
Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795
[TBL] [Abstract][Full Text] [Related]
9. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1.
Bissonnette M; Khare S; von Lintig FC; Wali RK; Nguyen L; Zhang Y; Hart J; Skarosi S; Varki N; Boss GR; Brasitus TA
Cancer Res; 2000 Aug; 60(16):4602-9. PubMed ID: 10969813
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
11. Increased p21(ras) activity in human fibroblasts transduced with survivin enhances cell proliferation.
Temme A; Diestelkoetter-Bachert P; Schmitz M; Morgenroth A; Weigle B; Rieger MA; Kiessling A; Rieber EP
Biochem Biophys Res Commun; 2005 Feb; 327(3):765-73. PubMed ID: 15649412
[TBL] [Abstract][Full Text] [Related]
12. [Ras p21 and signal transduction].
Kishi K; Tanaka K; Takai Y
Gan To Kagaku Ryoho; 1993 Jun; 20(8):1107-21. PubMed ID: 8512342
[TBL] [Abstract][Full Text] [Related]
13. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.
Gallagher AP; Burnett AK; Bowen DT; Darley RL
Cancer Res; 1998 May; 58(9):2029-35. PubMed ID: 9581849
[TBL] [Abstract][Full Text] [Related]
14. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
15. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
17. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
[TBL] [Abstract][Full Text] [Related]
18. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
Weiss B; Bollag G; Shannon K
Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
[TBL] [Abstract][Full Text] [Related]
19. The GAP1 family of GTPase-activating proteins: spatial and temporal regulators of small GTPase signalling.
Yarwood S; Bouyoucef-Cherchalli D; Cullen PJ; Kupzig S
Biochem Soc Trans; 2006 Nov; 34(Pt 5):846-50. PubMed ID: 17052212
[TBL] [Abstract][Full Text] [Related]
20. The alternative H-ras protein p19 displays properties of a negative regulator of p21Ras.
Huang MY; Cohen JB
Oncol Res; 1997; 9(11-12):611-21. PubMed ID: 9563009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
